Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

. Her work focuses on disparities and systemic inequities in care and access to the health system, as well as the impacts of health policy on various racial, gendered, and socioeconomic communities. She seeks perspectives from experts in internal medicine, health equity, community outreach, clinical research, mental health, and legislative policy.

, she delved into rare disease coverage at HCPLive

, a sister publication, where she fostered connections that extended beyond the research community into that of health advocacy, paving the way to her current role. Her work has been featured in 

NewsBreak, CHEST Today, Contemporary Pediatrics, Contemporary OB/GYN, Dermatology Times, Drug Topics, Managed Healthcare Executive, RamaOnHealthcare, and CGTLive.

She received her bachelor's degree in creative writing and psychology from Eckerd College and continued her postgraduate studies at the University of Florida's College of Journalism and Communications.

Articles

The 2025 guideline introduces notable updates including refined recommendations for dual antiplatelet therapy, cardiogenic shock management, and secondary prevention.

AHA, ACC Update Guidelines for Acute Coronary Syndrome Management

Several rare disease patient populations received their first-ever FDA-approved drug since Rare Disease Day last year, signifying progress in closing treatment gaps for rare disease. 

5 Rare Diseases That Now Have Their First FDA-Approved Treatments

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

Videos

Mile Brujic, OD, FAAO, discusses his new research being presented at the Southeastern Educational Congress of Optometry 2025 meeting concerning dry eye treatment.

New Research Covers Alternative Method of Treating Dry Eye

The cause of age-related macular degeneration can be varied and symptoms are often not recognized immediately, according to Hasenin Al-khersan, MD.

Symptoms of AMD Not Always Obvious to Patients

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

MASH

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

1.125rem

Jay T. Rubinstein, MD, PhD, is the Virginia Merrill Bloedel Professor of Otolaryngology and Bioengineering and Director, Bloedel Hearing Research Center, University of Washington School of Medicine.

Jay T. Rubinstein, MD, PhD, University of Washington School of Medicine, discusses DB-OTO, an investigational gene therapy with potential to treat otoferlin gene–related hearing loss.

Gene Therapy Holds Potential in Otoferlin-Related Hearing Loss